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THE CLINICAL PRESENTATION OF RENAL CELL CARCINOMA WITH
SIMULTANEOUS DIFFERENT HISTOLOGIC TYPE, A 15eYEAR DATABASE
ANALYSIS IN TAIPEI VETERANS GENERAL HOSPITAL
Yun-Chu Chang 1, Tzu-Chun Wei 1,2, Alex T.L. Lin 1,2, Kuang-Kuo Chen 1,2.
1Department of Urology, Taipei Veterans General Hospital, National Yang
Ming University, Taipei, Taiwan; 2Department of Urology, School of
Medicine, and Shu-Tien Urological Institute, National Yang Ming University,
Taipei, Taiwan
Purpose: Most of the current studies were aimed at single histologic type
renal cell carcinoma (RCC). The simultaneous different histologic RCCwere
barely discussed. This study was aimed to these patient with special
clinical features and outcome.
Materials andMethods: We retrospectively reviwed patient in the past 15
years who received operation for renal tumor in Taipei Veterans General
Hospital, and the pathology report revealed RCC with simultaneous tow
different cell type on the same kidney. The demographic data including age
at surgery, sex, body weight index (BMI), comorbidities, and the pre-
operative CT image ﬁndings were collected, as well as the operative
method, pathologic outcome, and further outcome while follow-up.
Results: Total 15 patients were included. The mean age at surgery was
59.3± 13.2 years and mean BMI was 25.3± 4.8 kg/m2. Fourteen patients
were male (86.7%) and 8 (53.3%) had their tumor on the left side. Among
the comorbidities, hypertension accounts for the highest incidence
(46.6%), followed by chronic kidney disease (end-stage renal disease or
polycystic kidney disease, 40%), coronary artery disease (26.7%), type 2
diabetes mellitus (20%) and malignant disease of other organ (20%). There
were only 2 patients (13.3%) having distinct 2 tumors from initial CT image,
and the pathology reported different cell type. Other patient (26.7%) had
incidental the other small tumor in the specimen or there were mixed
histologic feature in single tumor. The average diameter of the main tumor
was 5.1± 2.9 cm and the smaller one 1.4± 1.0 cm. There were 4 patients
(26.7%) having lymph node and distant metastasis at the meanwhile of
diagnosis. According to the AJCC cancer staging (2010), T1a tumor repre-
sented for 20%, T1b tumor 20%, T2a tumor 26.7%, and T3a tumor 6.7%. The
other smaller tumor were all of T1a stage. Most of tumor were classiﬁed as
Fuhrman grade 2 (66.7%), followed by grade 4 (20%) and grade 3 (13.3%).
The operative method were mainly open radical nephrectomy (40%), fol-
lowed by laparoscopic radical nephrectomy (26.7%), open partial ne-
phrectomy (13.3%), robotic-assisted partial nephrectomy (13.3%) and
robotic-assisted radical nephrectomy (6.7%).
The two differnt pathologic cell type of each patient were clear cell with
papillary RCC (20%), clear cell with chromophobe RCC (20%), clear cell with
mucinous tubular and spindle carcinoma (13.3%), and clear cell with clear
cell papillary RCC (13.3%), clear cell and collecting duct carcinoma (6.7%),
papillary and mucinous tubular and spindle carcinoma (6.7%), papillary
and acquired cystic renal disease related carcinoma (6.7%), clear cell and
acquired cystic renal disease related carcinoma (6.7%), and clear cell,
papillary and mucinous tubular and spindle carcinoma (6.7%).
The average follow-up interval was 29.1± 21.1 months. The recurrence
were found in 2 patients, one with clear cell and mucinous tubular and
spindle carcinoma at the 55th month post-OP and the other with papillary
cell and acquired cystic renal disease related carcinoma at the 30th month,
respectively. Three patients with initial distant metastasis expired about 6
months after the surgery, in average.
Conclusion: Simultaneous two histological cell types RCC on the same
kidney was relately rare. Our 15-year data showed various combinations of
two histolytic cell type. However, it is difﬁcult to correlate the prognosis
and clinical outcome with the combination of cell types due to the limited
data of recurrence and 5-year cancer speciﬁc mortality rate.
NDP009:
THE SAFETY AND EFFICACY OF LOW DOSE BCG INTRAVESICAL
INSTILLATION FOR THE TREATMENT OF UREMIC OR KIDNEY
TRANSPLANT PATIENTS WITH RECURRENT UROTHELIAL CARCINOMA
OF THE BLADDER
Wei-Ting Kuo, Chia-Cheng Yu, Tony T. Wu. Division of Urology, Department
of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROCPurpose: Theoretically, immunosuppression is a relative contraindication
for intravesical BCG therapy because of the risk of severe morbidity and
sepsis. We present our experience with intravesical BCG therapy in ure-
mia/renal transplant patients with recurrent urothelial carcinoma of
Bladder.
Materials and Methods: A total of 34 patients with recurrent superﬁcial
bladder cancer (pTa or pT1) were enrolled. Ten patients are uremic and the
other 14 were renal transplantation patient. Intravesical instillation with
low dose (1/2 or 1/3 of 81mg) of BCG was administered weekly for 6
weeks, postoperatively. Boost dose was given at 3 months interval and
then every 6 months until 2 years postoperatively. Cystoscopic examina-
tion was performed every 3 months for the ﬁrst year and semiannually for
2 years and then annually.
Results: Low dose BCG intravesical instillation was completed in 30 pa-
tients. Tumor recurrence was recognized in 2 patients during followup,
who restarted second BCG induction therapy without recurrence. BCG
therapy was withdrawn in 4 patients due to BCG-related local toxicity. No
major complication or systemic dissemination of TB bacili was noted.
Transient dysuria and hematuria are the most common adverse events.
Conclusion: Uremia/renal transplantation patients were traditionally
considered as immuno-compromised and high risk for tumor recurrence.
Low dose BCG intravesical instillation in such patients seems to be a safe
prophylaxis with similar efﬁcacy on tumor control.
NDP010:
THE SERUM MICRORNA IN PROSTATE CANCER PATIENTS AS A
BIOMARKER FOR EARLY DETECTION
Jui-Ming Liu 1, Ren-Jun Hsu 2. 1Division of Urology, Department of Surgery,
Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan,
Taiwan; 2Department of Pathology and Graduate Institute of Pathology and
Parasitology, Tri-Service General Hospital, National Defense Medical Center,
Taipei, Taiwan
Purpose: Prostate cancer is the 6th most cancer death in Taiwan. There are
no signiﬁcant symptoms and signs in early prostate cancer. MicroRNA is
stable in the cell or tissue and not easily to be degraded. To identify
whether microRNA a potential biomarker for early detection of prostate
cancer, we conducted this study.
Materials and Methods: We collected serum from two different prostate
cancer patients. Serum from other four non-prostate cancer patients was
collected as control group. The QRT-PCR array (782 micro RNAs) was used
to select high speciﬁc expressed microRNAs from serum of prostate cancer
patient. We used above speciﬁc microRNAs to detect serum from 20
prostate cancer patients and 40 non-prostate cancer subjects.
Results: There were 13 microRNAs highly expressed in serum of prostate
cancer patients than control group. After ampliﬁcation, there were only 2
microRNAs highly correlation with prostate cancer. We overexpressed
these 2 microRNAs in LNCaP, increased carcinogenesis in LNCaP was noted.
Conclusion: The microRNA is a potential biomarker in early detection of
prostate cancer.
NDP011:
THE MOLECULAR MECHANISM OF THE INHIBITORY EFFECT ON
PROSTATE CANCER CELL GROWTH THROUGH THE DIRECT ACTION OF
ESTROGEN ON ESTROGEN RECEPTOR
Jui-Ming Liu 1, Ren-Jun Hsu 2. 1Division of Urology, Department of Surgery,
Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan,
Taiwan; 2Department of Pathology and Graduate Institute of Pathology and
Parasitology, Tri-Service General Hospital, National Defense Medical Center,
Taipei, Taiwan
Purpose: Hormone replacement therapy is one of treatment choice of
prostate cancer. Estrogen has inhibition of prostate cancer by affect pitu-
itary gland. This negative feedback is lowering level of testosterone not
directly act on prostate cancer cell. To determine whether estrogen has
direct effect on prostate cancer cell, we conducted this study.
Materials and Methods: Choice of two prostate cancer research as the
main material, the ﬁrst detection of estrogen receptors, to see the estrogen
receptor (ER) expression in the case of prostate cells to clarify the
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mance. Clarify the ER estrogen stimulation of prostate cancer will be as
before this laboratory study in renal cancer cells by inhibiting AKT
pathway to inhibit tumor role.
Results: We found prostate cancer growth was inhibited by certain level of
Estrogen. The survival of prostate cancer was reduced up to 30%. Besides,
migration and invasion of prostate cancer cell were also inhibited by Es-
trogen. Estrogen also stimulate VEGFR signal of prostate cancer cell.
Conclusion: Estrogen has direct inhibitory effect on prostate cancer cell
growth. Further studies to identify the mechanism of Estrogen, androgen
receptor, RAS, EGFR pathway are needed.
NDP012:
EVALUATION OF FLUORODEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR DIAGNOSIS AND
STAGING OF UPPER URINARY TRACT UROTHELIAL CARCINOMA
Kuan-Hsun Huang, Chien-Hui Ou, Wen-Horng Yang. Department of
Urology, Medical College and Hospital, National Cheng-Kung University,
Tainan, Taiwan
Purpose: To evaluate the ability of Fluorodeoxyglucose positron emission
tomography /computed tomography (18F-FDG PET-CT) in primary diag-
nosis and detection of upper urinary tract urothelial carcinoma by
comparing with ﬁnal pathological result.
Materials and Methods: We retrospectively evaluated clinicopathological
records of patients in our institute. All patients suspicious to have upper
urinary tracts malignancies were received 18F-FDG PET-CT, which was
followed by pathological-proved procedures such as ureteroscopic biopsy,
CT-guide biopsy, Nephroureterectomy or Hand-assisted Retroperitoneo-
scopic Nephroureterectomy (HARN). 21 patients were included in this
study. There were 12 women and 9 men with a median age of 76 years old
(range 34~89y/o).
Results: Of 21 patients in study group, 12 patients received HARN, 3 had
URS biopsy, 1 CT-guide biopsy and 5 open Nephroureterectomy. There
were 5, 3, 5, 7 patients with pTa, pT1, pT2, pT3 respectively. 3 patients were
diagnosed with lymph nodes metastasis by PET-CT, and 2 patients with
tissue proved lymph node metastasis. 20 showed deﬁnite FDG uptake in
initial or delay phase. Positive predictive rate was 95 %.
Conclusion: These preliminary results of this study with small number of
patients showed that FDG-PET/CT is another effective diagnosis in detec-
tion of UTUC.
NDP013:
THE PROGNOSTIC IMPACT OF MULTIFOCALITY FOR UPPER TRACT
UROTHELIAL CARCINOMA PATIENTS AFTER RADICAL
NEPHROURETERECTOMY
Ta-Yao Tai, Chien-Hui Ou. Department of Urology, National Cheng Kung
University Hospital, Tainan, Taiwan
Purpose: To evaluate the association between tumor multifocality of up-
per urinary tract urothelial carcinoma (UTUC) patients underwent radical
nephroureterectomy and validate the impact on oncologic outcomes in
those patients.
Materials and Methods: Patients who underwent nephroureterectomy
between November 2003 and November 2013 were identiﬁed from Na-
tional Cheng Kung University Hospital (NCKUH). Outcomes were ob-
tained via retrospective analysis of notes and electronic records. Overall
survival (OS), bladder recurrence-free survival (BRFS) were estimated
using KaplaneMeier methods and grade-stratiﬁed differences were
analyzed using the log-rank test. Tumor multifocality of UTUC was
deﬁned as the synchronous presence of multiple tumors in the renal
pelvis or ureter.
Results: Between November 2003 and November 2013, 269 patients un-
derwent nephroureterectomy of UTUC with a median age at diagnosis of
68 years. Median (range; mean) follow-up was 29 (2e120; 35.3) months.
In total, 34.5% (n¼ 69) of the patients had multifocal disease. The esti-
mated OS in multifocal tumor group and single tumor group were 58.8%
and 77.6%, respectively, at 5 years, and 44.1% and 59.7%, respectively, at 10
years (p¼ 0.0225). The estimated mean BRFS in multifocal tumor patientsand single tumor patients was 50.7% and 79.5%, respectively at 2 years and
47.8% and 74.5%, respectively, at 5 years (p<0.0001).
Conclusion: In this present single center cohort study, tumor multifocality
is an independent prognostic indicator of overall survival and bladder
recurrence-free survival in patients with UTUC treated with nephrour-
eterectomy.
NDP014:
CLINICAL FEATURES OF PATIENTS WITH NON-MALIGNANT UPPER
TRACT LESIONS MIMICKING UROTHELIAL CANCER
Ze-Hong Lu, Chien-Hui Ou. Department of Urology, National Cheng Kung
University Hospital, College of Medicine, National Cheng Kung University,
Tainan, Taiwan
Purpose: The aim of this retrospective study was to evaluate the incidence
and clinical features of patients undergone nephroureterectomy with non-
malignant upper tract lesions presumed to be urothelial carcinoma. The
clinicopathologic characteristics of these lesions were also determined.
Material and methods: Between Oct 2004 and Oct 2015, 350 patients
underwent retroperitoneoscopic nephroureterectomy for possible upper
urinary tract urothelial carcinoma without routinely ureteroscopic biopsy
of lesions at our institute. Twenty-three (6.6%) had non-malignant benign
lesions at the ﬁnal pathologic examination. The preoperative features of
these patients were investigated, including imaging ﬁndings, urine cyto-
logic results, and renal function status and previous history.
Results: The 23 patients comprised 9 men and 14 women. Initial symp-
toms included gross hematuria, hydronephrosis or repeated pyelone-
phritis. Urine cytologywere also collected for evaluation.We also reviewed
available abdomen computed tomography and retrograde pyelogram.
Three patients underwent preoperative ureteroscopy. 11 patients
(including 2 patient was post kidney transplantation status) had non-
functional kidney. We divided patient into two groups by renal function
status. The most common pathologic feature of ESRD group is atrophic
kidney. In the other hand, the most common diagnosis of the other group
of non-ERSD is pyelonephritis.
Conclusion: Non-malignant pathologic lesions were detected in twenty-
three (6.6%) patients who had undergone retroperitoneoscopic neph-
roureterectomy without preoperative ureteroscopic biopsies of uppertract
lesions.
NDP015:
CLINICAL AND THERAPEUTIC IMPLICATIONS OF NEUROENDOCRINE
PROSTATE CANCER: A LONG WINDING ROAD TO CURE
Chia-Lung Tsai, Kevin Lu, Hua-Pin Wang, Victor Chia-Hsiang Lin,
Tsan-Jung Yu. Division of Urology, Department of Surgery, E-Da Hospital,
School of Medicine, I-Shou University, Kaohsiung city, Taiwan
Purpose: Primary neuroendocrine cancer of prostate is an extremely rare
variant of prostate cancer, comprising 0.5% to 2% of prostate malignancies.
This entity encompasses various clinical contexts, ranging from the de
novo small cell carcinoma (SCC) to a treatment-emergent transformed
phenotype that arising from typical adenocarcinoma (Ad) of the prostate.
The rarity of these neoplasms poses a diagnostic and therapeutic chal-
lenge. Little is known about neuroendocrine prostate cancer and the cur-
rent knowledge of this disease is based on case reports or small series. Our
purpose was to characterize the cases treated at a tertiary academic center
and to evaluate patient outcomes with the available treatment modalities.
Materials and Methods: This was a single-institute retrospective obser-
vational cohort study of patients with neuroendocrine prostate cancer
followed at E-Da Hospital, Kaohsiung city, Taiwan between January 1, 2008
and October 1, 2013. Patient and tumor data were analyzed using
descriptive statistical methods.
Results: Among 826 prostate cancers, six patients were identiﬁed with
primary neuroendocrine prostate cancer, comprising 3 from de novo
mixed variety (SCC and Ad) and 3 from transformed phenotype (pure SCC).
The median age at diagnosis was 73.5 years. The most common presenting
symptoms were obstructive symptoms (weak stream, incomplete empty
and urine retention). The morphological appearance of the tumor cells and
their immunohistochemical reactivity for neuroendocrine markers, and
